Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Gilead

How To Invest: The Slow Saucer Base Can Produce Quick Returns

Though it can technically be as short as seven weeks, most saucer bases develop over months or even years.

Investors Business Daily

Is Gilead's 10% Crash — Resulting In A Failed Breakout — An Overreaction?

Gilead said Monday its drug, Trodelvy, failed to pass muster in a study of patients with lung cancer, and GILD stock toppled.

Investors Business Daily

Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead

Arcellx and Gilead's Kite division deepened their collaboration in cancer treatments on Wednesday. ACLX stock rocketed into a breakout.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Gilead Tumbles After An Unpredictable Element Drove Its Third-Quarter Beat

Investors hammered GILD stock on Wednesday after Gilead beat third-quarter expectations on the back of its Covid treatment, Veklury.

Investors Business Daily

Gilead Sciences (GILD) Earnings Forecast and Gameplan

Gilead Sciences (GILD) boasts an impressive product portfolio and has surpassed the consensus estimate on the topline in each of the trailing four quarters. With the company gearing up to post its third quarter results, is GILD a wise investment now? Read on.

StockNews.com

Using Market Volatility to Your Advantage: Selling a GILD Put Option Before Earnings

A trader selling the November 10th, $76-strike put on GILD would receive around $105 into their account, which would be theirs to keep.

Barchart

Why AstraZeneca's Disappointing Lung Cancer Update Also Tripped Gilead Stock

AstraZeneca stock tumbled Wednesday after its experimental drug led to only a month's benefit over chemotherapy in lung cancer patients.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

How to Enhance Your Own Strategies with POWR Ratings

Wall Street is never lacking in strategy or trading ideas. In investing, if you can combine two or more strategies that align around a particular investing idea, you can enhance your likelihood of success. This idea combines our POWR Ratings with a strategy that is currently making the rounds on…

StockNews.com

Top 3 Biotech Stocks Leading the Way This October

The biotech industry is well-positioned for strong growth thanks to increasing demand for high-quality treatments for chronic diseases. Given this backdrop, quality biotech stocks Jazz Pharmaceuticals (JAZZ), Amgen (AMGN), and Gilead Sciences (GILD) could be solid buys for October. Read on….

StockNews.com

The Unexpected Reason Gilead Just Notched Its Biggest Single-Day Move In A Month

Investors don't fully appreciate Gilead Sciences' leadership in HIV treatment, an analyst said Friday as he upgraded GILD stock.

Investors Business Daily

3 Best Biotech Stocks for Growth in 2023

The biotech industry is well-positioned for solid growth due to the growing demand for high-quality treatments for chronic diseases and an aging population. Therefore, it could be wise to invest in fundamentally strong biotech stocks Jazz Pharmaceuticals (JAZZ), Alkermes (ALKS), and Gilead Sciences (GILD), given their solid growth prospects. Read…

StockNews.com

Big Pharma’s playbook for expensive meds

Here are just a few of the many examples of drug pricing practices that have driven consumers to demand change

Salon

Major brands are pulling ads on Musk's X after posts appeared beside pro-Nazi content

"If trust is lost it's like a house of cards—and currently X lacks trust from both its audiences and its B2B partners."

Fortune

Gilead Plots A Massive Move Into Oncology: A Third Of Sales By 2030

Gilead expects a third of sales to come from its cancer treatments by 2030, and GILD stock jumped Friday despite a mixed earnings report.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Buy, Hold or Sell? Gilead Sciences Inc. (GILD) and Moderna Inc. (MRNA)

Rapid breakthroughs and surging demand position the biotech sector for significant expansion in the near term. Therefore, quality biotech stock Gilead Sciences (GILD) could be worth buying. However, I think it will be best to wait for a better entry point in Moderna (MRNA). Read on.

Investors Business Daily

Gilead Stock Dives As Light Profit Overshadows Strong Cancer Drug Sales

Biotech giants Gilead Sciences and Amgen posted mixed quarters on Thursday — leading GILD stock and Amgen stock to topple.

Investors Business Daily

Get Income On Gilead Stock, Or Buy It At A Discount With This Option Trade

High volatility means higher-than-normal option premiums, which can be great for option sellers.

StockNews.com

3 of the Best Stocks in 1 of Wall Street's Worst-Rated Industry

After years of robust growth, the biotech industry has struggled since last year due to several headwinds, including regulatory concerns, inflation, and the Fed’s aggressive rate hikes, which have sucked out speculative capital. Despite currently being one of the poorly-rated industries, investors could consider buying top-biotech stocks Gilead (GILD), Vertex…

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

2 Dividend Stocks That Could Pay You for the Rest of Your Life

As the market remains volatile due to ongoing concerns about elevated inflation, prolonged rate hikes, and an impending recession, fundamentally strong dividend stocks Bristol-Myers Squibb (BMY) Gilead Sciences (GILD) might be ideal buys to ensure a stable income stream. Moreover, these stocks could be great long-term investments. Read more.

StockNews.com

1 Resilient Growth Stock to Buy Now and Hold Forever

Biopharmaceutical giant Gilead Sciences’ (GILD) shares have risen nearly 30% over the past year despite lingering macroeconomic challenges. Moreover, the company delivered solid growth last year and is expected to maintain its business momentum in 2023 and beyond, driven by its diversified medicines portfolio. Hence, investors could consider buying and…

Investors Business Daily

Gilead Snags Another Cancer Win On The Heels Of Its Best Growth In 7 Years

Gilead Sciences followed up a strong quarterly report with a third FDA approval for cancer drug Trodelvy, and GILD stock popped.

WEKU

At buzzy health care business conference, investors fear the bubble will burst

JPMorgan's cheery confab returned to San Francisco, but the health care capitalists had economic anxiety, too.

Salon

Health care investors convene in SF

Health care’s business class returned to San Francisco last week for JPMorgan’s annual health care confab

StockNews.com

Want Passive Income in a Bear Market? Check out This Biotech Stock

With the minutes of the latest Fed meeting showing that interest rates will keep increasing this year, the economy is widely expected to enter a recession. Amid the expected downturn this year, it could be wise to buy biotech stock Gilead Sciences (GILD) due to its solid growth prospects and…

StockNews.com

2 Biotech Stocks to Buy Amid a Blazing Hot Run

A rapidly aging population and the rise in lifestyle diseases drive the biotech industry’s growth. Through their cutting-edge research, biotech companies are coming up with new solutions to develop treatments. Given the solid long-term prospects of the industry, it could be wise to buy fundamentally strong biotech stocks Amgen Inc.…

1 2 3 4 5

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.